Eligible participants will be adults ( 18years ) with type 1 diabetes treated with insulin pump therapy and suboptimal glycaemic control ( glycated haemoglobin ( HbA1c ) 7.5 % ( 58mmol/mmol ) and 10 % ( 86mmol/mmol ) ) .